Decreased circulating dipeptidyl peptidase-4 enzyme activity is prognostic for severe outcomes in COVID-19 inpatients.
Biomark Med
; 16(5): 317-330, 2022 04.
Article
in English
| MEDLINE | ID: covidwho-1703144
ABSTRACT
Aim:
To investigate the serum circulating DPP4 activity in patients with COVID-19 disease. Materials &methods:
Serum samples from 102 hospitalized COVID-19 patients and 43 post-COVID-19 plasma donors and 39 SARS-CoV-2 naive controls and their medical data were used. Circulating DPP4 activities according to different COVID-19 disease peak severity (WHO) groups at sampling and at peak were assessed.Results:
A significant decrease (p < 0.0001) in serum DPP4 activity was found in study groups of higher disease severity. When the circulating DPP4 activity was assessed as a prognostic marker, the logistic regression (p = 0.0023) indicated that the enzyme activity is a predictor of mortality (median 9.5 days before death) with receiver operating characteristic area under the curves of 73.33% (p[area = 0.5] < 0.0001) as single predictor and 83.45% (p[area = 0.5] < 0.0001) in combination with age among hospitalized patients with COVID-19.Conclusion:
Decreased circulating DPP4 activity is associated with severe COVID-19 disease and is a strong prognostic biomarker of mortality.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Biomarkers
/
Dipeptidyl Peptidase 4
/
COVID-19
/
Inpatients
Type of study:
Diagnostic study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Long Covid
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Biomark Med
Journal subject:
Biochemistry
/
Medicine
Year:
2022
Document Type:
Article
Affiliation country:
Bmm-2021-0717
Similar
MEDLINE
...
LILACS
LIS